Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Treatment of coronary in-stent restenosis with drug-eluting balloon catheter: real-world outcome and literature review.

Xia HY, Low AF, Lee CH, Teo SG, Chan M, Chan KH, Tan HC.

Ann Acad Med Singapore. 2013 Jan;42(1):49-51. No abstract available.

2.

Long-Term Results of Drug-Coated Balloons for Drug-Eluting In-Stent Restenosis: Gaining Perspective.

Alfonso F, Cuesta J.

JACC Cardiovasc Interv. 2015 Jun;8(7):885-8. doi: 10.1016/j.jcin.2015.02.013. Epub 2015 May 20. No abstract available.

3.

Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial.

Ellis SG, O'Shaughnessy CD, Martin SL, Kent K, McGarry T, Turco MA, Kereiakes DJ, Popma JJ, Friedman M, Koglin J, Stone GW; TAXUS V ISR Investigators.

Eur Heart J. 2008 Jul;29(13):1625-34. doi: 10.1093/eurheartj/ehn231. Epub 2008 Jun 13.

PMID:
18556716
4.

Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.

Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U.

N Engl J Med. 2006 Nov 16;355(20):2113-24. Epub 2006 Nov 13.

5.

Drug-eluting balloons: effective and durable treatment for in-stent restenosis.

Samady H, Mekonnen G.

JACC Cardiovasc Interv. 2013 Jun;6(6):577-9. doi: 10.1016/j.jcin.2013.04.002. No abstract available.

6.

Fixer upper methods.

Butman S.

Catheter Cardiovasc Interv. 2014 May 1;83(6):888. doi: 10.1002/ccd.25483. No abstract available.

PMID:
24753168
7.

Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.

Airoldi F, Briguori C, Iakovou I, Stankovic G, Biondi-Zoccai G, Carlino M, Chieffo A, Montorfano M, Cosgrave J, Michev I, Rogacka R, Sangiorgi GM, Colombo A.

Am J Cardiol. 2006 Apr 15;97(8):1182-7. Epub 2006 Mar 9.

PMID:
16616023
8.

Use of the Crossboss catheter in coronary chronic total occlusion due to in-stent restenosis.

Papayannis A, Banerjee S, Brilakis ES.

Catheter Cardiovasc Interv. 2012 Aug 1;80(2):E30-6. doi: 10.1002/ccd.23188. Epub 2011 Dec 12.

PMID:
22162302
9.

Randomized comparison between intracoronary beta-radiation brachytherapy and implantation of paclitaxel-eluting stents for the treatment of diffuse in-stent restenosis.

Schukro C, Syeda B, Kirisits C, Schmid R, Pichler P, Pokrajac B, Lang I, Pötter R, Glogar D.

Radiother Oncol. 2007 Jan;82(1):18-23. Epub 2006 Sep 12.

PMID:
16971011
10.

Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.

Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A; LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators.

J Am Coll Cardiol. 2009 May 12;53(19):1760-8. doi: 10.1016/j.jacc.2009.01.035.

11.

Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.

Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, Maddux JT, Cutlip DE, Simonton CA, Sood P, Kereiakes DJ; SPIRIT IV Investigators.

J Am Coll Cardiol. 2011 Jun 28;58(1):19-25. doi: 10.1016/j.jacc.2011.02.022. Epub 2011 Apr 21.

12.

Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials.

Onuma Y, Serruys PW, Kukreja N, Veldhof S, Doostzadeh J, Cao S, Stone GW; SPIRIT II and III Investigators.

Eur Heart J. 2010 May;31(9):1071-8. doi: 10.1093/eurheartj/ehp599. Epub 2010 Jan 29.

PMID:
20118171
13.

Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.

Markovic S, Paliskyte R, Rottbauer W, Wöhrle J.

Cardiovasc Revasc Med. 2012 Nov-Dec;13(6):307-10. doi: 10.1016/j.carrev.2012.09.003.

PMID:
23164475
14.

Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).

Waksman R, Ghali M, Goodroe R, Ryan T, Turco M, Ring M, McGarry T, Dobies D, Shammas N, Steinberg DH, Swymelar S, Kaneshige K, Torguson R.

Am J Cardiol. 2012 Oct 15;110(8):1119-24. doi: 10.1016/j.amjcard.2012.05.050. Epub 2012 Jul 3.

PMID:
22762711
15.

Letter by Alfonso et al regarding article, "Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis".

Alfonso F, Pérez-Vizcayno MJ, Fernández C.

Circulation. 2010 Feb 16;121(6):e33; author reply e34-5. doi: 10.1161/CIR.0b013e3181d22b44. No abstract available.

16.
17.

Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease.

Zhang F, Dong L, Qian J, Ge J.

Ann Med. 2011 Feb;43(1):75-9. doi: 10.3109/07853890.2010.543924. Epub 2010 Dec 20.

PMID:
21171912
18.

One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).

Ahmed WH, Zambahari R, Al-Rashdan I, Al Naeemi A, Saeed FA, Mascioli S.

J Interv Cardiol. 2008 Dec;21(6):512-8. doi: 10.1111/j.1540-8183.2008.00395.x. Epub 2008 Oct 2.

PMID:
18973513
19.

Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.

Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A; ISAR-DIABETES Study Investigators.

N Engl J Med. 2005 Aug 18;353(7):663-70. Epub 2005 Aug 16.

20.

Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon.

Cremers B, Clever Y, Schaffner S, Speck U, Böhm M, Scheller B.

Minerva Cardioangiol. 2010 Oct;58(5):583-8.

PMID:
20948504

Supplemental Content

Support Center